Literature DB >> 11437293

Nitric oxide synthase inhibition attenuates vasoactive response to spinal cord stimulation in an experimental cerebral vasospasm model.

H M Göksel1, O Karadag, U Turaçlar, F Taş, I Oztoprak.   

Abstract

BACKGROUND: The basic mechanism of delayed cerebral vasospasm following subarachnoid haemorrhage (SAH) has been intensively investigated. It is thought that nitric oxide (NO) is a basic mediator of the cerebral vasodilator mechanism. Previous clinical and experimental studies have shown a cerebral vasodilator effect of high cervical spinal cord stimulation (SCS) however, the mechanism of this effect is still controversial. We investigated the contribution of the vasodilator effect of NO to this mechanism in an experimental SAH model using rabbits.
METHOD: Four experimental groups, were designated: Group 1. Cerebral blood flow (CBF) was evaluated by transcranial Doppler ultrasonography (TDU) in 8 rabbits. Group 2. In 4 animals, intracisternal saline injection and cervical epidural electrode placement without SCS were performed before TDU. Group 3. TDU was performed before and after SCS on the fourth day of SAH in 8 rabbits. Group 4. In 8 animals, N-Nitro-L-Arginine Methyl Esther (L-NAME) was administered intracisternally on the fourth day of SAH, at a dose of 0.6 mg/kg, 45 minutes before SCS. CBF parameters, obtained via measurements or calculations from TDU data, were compared.
FINDINGS: The occurrence of vasospasm after SAH was demonstrated with significant changes in TDU parameters (high peak systolic velocity and positive values of the degree of stenosis). In all SAH animals, SCS resulted in significant vasodilation. Even after the injection of L-NAME, SCS still had a significant vasodilatory effect in SAH animals, but there was also a significant difference in CBF parameters in the SCS-only group when compared with the L-NAME treatment before SCS group.
INTERPRETATION: The mechanism of the cerebral vasodilatory effect of SCS remains controversial. Our results revealed the contribution of a neurohumoral effect which can be partially prevented by use of an NO synthase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437293     DOI: 10.1007/s007010170094

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  6 in total

Review 1.  Contemporary insights into painful diabetic neuropathy and treatment with spinal cord stimulation.

Authors:  Kai McGreevy; Kayode A Williams
Journal:  Curr Pain Headache Rep       Date:  2012-02

2.  Prehemorrhage statin use and the risk of vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  Shaye I Moskowitz; Christine Ahrens; J Javier Provencio; Michael Chow; Peter A Rasmussen
Journal:  Surg Neurol       Date:  2008-04-18

3.  Roles of dorsal column pathway and transient receptor potential vanilloid type 1 in augmentation of cerebral blood flow by upper cervical spinal cord stimulation in rats.

Authors:  X Yang; J P Farber; M Wu; R D Foreman; C Qin
Journal:  Neuroscience       Date:  2008-01-12       Impact factor: 3.590

Review 4.  Putative mechanisms behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies.

Authors:  Mingyuan Wu; Bengt Linderoth; Robert D Foreman
Journal:  Auton Neurosci       Date:  2008-02-29       Impact factor: 3.145

5.  Electrical modulation of the sympathetic nervous system in order to augment cerebral blood flow: a protocol for an experimental study.

Authors:  Mark Ter Laan; J Marc C van Dijk; Michiel J Staal; Jan-Willem J Elting
Journal:  BMJ Open       Date:  2011-07-22       Impact factor: 2.692

6.  Spinal cord stimulation exerts neuroprotective effects against experimental Parkinson's disease.

Authors:  Aiko Shinko; Takashi Agari; Masahiro Kameda; Takao Yasuhara; Akihiko Kondo; Judith Thomas Tayra; Kenichiro Sato; Tatsuya Sasaki; Susumu Sasada; Hayato Takeuchi; Takaaki Wakamori; Cesario V Borlongan; Isao Date
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.